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Abstract
Objective: To investigate the safety of combining a 6-Hz primed low-frequency repetitive transcranial magnetic stimulation (rTMS) intervention in the
contralesional hemisphere with a modified constraint-induced movement therapy (mCIMT) program in children with congenital hemiparesis.
Design: Phase 1 randomized, double-blinded, placebo-controlled pretest/posttest trial.
Setting: University academic facility and pediatric specialty hospital.
Participants: Subjects (NZ19; age range, 8e17y) with congenital hemiparesis caused by ischemic stroke or periventricular leukomalacia. No
subject withdrew because of adverse events. All subjects included completed the study.
Interventions: Subjects were randomized to 1 of 2 groups: either real rTMS plus mCIMT (nZ10) or sham rTMS plus mCIMT (nZ9).
Main Outcome Measures: Adverse events, physician assessment, ipsilateral hand function, stereognosis, cognitive function, subject report of
symptoms assessment, and subject questionnaire.
Results: No major adverse events occurred. Minor adverse events were found in both groups. The most common events were headaches (real:
50%, sham: 89%; PZ.14) and cast irritation (real: 30%, sham: 44%; PZ.65). No differences between groups in secondary cognitive and
unaffected hand motor measures were found.
Conclusions: Primed rTMS can be used safely with mCIMT in congenital hemiparesis. We provide new information on the use of rTMS in
combination with mCIMT in children. These findings could be useful in research and future clinical applications in advancing function in
congenital hemiparesis.
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OpeThe doubly disabled adult brain after unilateral stroke is affected
not only by the lesion itself, but also by exaggerated interhemi-
spheric inhibition from the contralesional primary motor cortex
(M1) acting on the ipsilesional M1.1 In children with congenital
hemiparesis, a similar inhibition may occur through develop-
mental disuse, in which a child predominantly uses the less
affected extremities, masking potential function in the affected
extremities.2 Low-frequency (inhibitory) contralesional repetitive
transcranial magnetic stimulation (rTMS) has shown promising
cortical effects by inhibiting the contralesional M1, therebyn access under CC BY-NC-ND license.
Fig 1 Study design. Screening was followed by a 2-day series of
pretesting: imaging, physician assessment, and cognitive and motor
testing. rTMS sessions (light blocks) were 20 minutes total: priming
for 10 minutes at 6Hz at 90% of the RMT, followed by low-frequency
1-Hz rTMS for 10 minutes at 90% of the RMT. mCIMT (dark blocks) was
performed for 2 hours with 1:1 therapist-subject treatments. The
constraint cast was applied on treatment day 2 and was removed
on treatment day 10 (13 days total wear, including weekends).
Abbreviations: rTMSreal, real rTMS group; rTMSsham, sham rTMS group.
Pediatric brain stimulation safety S105disinhibiting surviving neurons in the ipsilesional M1.3-5 More
studies are investigating the use of rTMS as an intervention to
restore higher excitability in the ipsilesional M1.
Iyer et al6 found that the effects of 1-Hz low-frequency stim-
ulation can be enhanced through preceding the low-frequency
session with a priming 6-Hz high-frequency session. The use of
6-Hz priming of low-frequency rTMS to the contralesional
hemisphere in children with stroke may work by creating greater
disruption of the exaggerated interhemispheric effects of the
contralesional hemisphere on the ipsilesional hemisphere. In an
effort to achieve improved outcomes, 6-Hz priming rTMS used
immediately prior to the low-frequency rTMS can be used to
capitalize on principles of homeostatic plasticity.7 Homeostatic
plasticity encompasses several mechanisms aimed at stabilizing
neuronal activity to maintain synaptic specificity and prevent
unconstrained synaptic plasticity from predominating in the sys-
tem.8 Importantly, homeoplastic plasticity depends on the previ-
ous history of synaptic activity.9
Therefore, excitatory priming stimulation biases the neural
network to seek return to its baseline activity level. In combina-
tion, the low-frequency rTMS applied in the facilitated state yields
a more pronounced inhibition compared with low-frequency
rTMS that is not preceded by high-frequency rTMS.6
Distinct from rTMS, motor learning with use of constraint is an
additional intervention with potent effects on brain reorganiza-
tion.10-12 Modified constraint-induced movement therapy
(mCIMT) is defined as <3 hours of therapy per day using the
techniques of shaping, repetition, and constraint.13 The combining
of electrophysiological and behavioral interventions provides a
synergistic approach that may help to maximize the recovery of
hand function. Both interventions are aimed at suppression of the
exaggerated inhibitory interhemispheric effects, allowing
increased contribution from the surviving neuronal networks
within the ipsilesional hemisphere.
The important question of safety remains with such in-
terventions. The safety of rTMS has been investigated to a much
greater extent in adults with stroke than children; however, un-
derstanding the risks is paramount for all ages.14-16 Kirton et al17
demonstrated that 1-Hz low-frequency contralesional M1 rTMS
was safe, with no serious adverse events (eg, seizure) in children
with stroke. Although there are reports in adults with brain injury
that using 6-Hz priming rTMS with 1 treatment18 and multiple
treatments19 is safe, primed rTMS has not been explored in chil-
dren with stroke. Because of the high-frequency nature of the
priming and the greater potential risk of adverse events (eg,
seizure), investigating the safety of a 6-Hz primed, 1-Hz low-
frequency application of rTMS in combination with motor
learning training should be thoroughly investigated.
The purpose of this article is to report on the safety of 6-Hz
primed low-frequency rTMS combined with mCIMT specific to
children with hemiparesis. We defined safety by physician
assessment, cognitive status, a subject report of symptoms, and aList of abbreviations:
AMT active motor threshold
mCIMT modified constraint-induced movement therapy
MRI magnetic resonance imaging
M1 primary motor cortex
RMT resting motor threshold
rTMS repetitive transcranial magnetic stimulation
TMS transcranial magnetic stimulation
www.archives-pmr.orgquestionnaire. Because the rTMS component of the intervention
was delivered on the contralesional hemisphere, safety also
included assessment of ipsilateral, unaffected, hand function.
Methods
This study was a randomized, controlled, blinded, pretest-posttest
trial comparing active and placebo rTMS in combination with
mCIMT in children with congenital hemiparesis. Subjects meeting
our criteria were randomized into 1 of 2 groups: real rTMS plus
mCIMT and sham rTMS plus mCIMT (fig 1). Specific exclusion
and inclusion criteria guided subject enrollment and participation
in stages (appendix 1). For example, during the initial screening,
we excluded children with disorders of cellular migration and
proliferation because exaggerated interhemispheric inhibition may
not be present in these nonstroke disorders and our intervention
may potentially not be applicable. Because children with perinatal
stroke typically experience seizure within the first 48 hours after
birth,20 excluding any history of seizure would yield very few
children to study. We limited seizure activity to none in the 2 years
prior to the study because the study neurologist deemed this
seizure-free period appropriate in regard to safety. At pretest, we
obtained a fluid-attenuated inversion recovery scan sequence for
assessment of the cerebral infarction and a gradient echo scan
sequence for evidence of any prior hemorrhage. The study pedi-
atric neurologist reviewed these results for each subject enrolled.
Evidence of hemorrhage and subsequent presence of hemosiderin
protein excluded any subjects because they may have been pre-
disposed to seizure.21,22 We allocated subjects using a random
numbers table system. Researchers administering the rTMS in-
terventions were unblinded. Testing researchers, physicians,
caregivers, and subjects were blinded to treatment allocation.
Subjects were recruited through institutional review boarde
approved mailings, community- and school-based contacts, and
diagnosis-specific website postings. The study’s pediatric neurol-
ogist completed a magnetic resonance imaging (MRI) session with
each subject, which included fluid attenuation inversion recovery
S106 B.T. Gillick et aland gradient echo sequences for identification of the location and
lesion type. After screening and approval, each child received
single pulses of transcranial magnetic stimulation (TMS) to the
ipsilesional M1 to confirm the presence of a motor-evoked po-
tential, evidenced by electromyographic monitoring from the
affected extensor digitorum muscle. If a resting motor threshold
(RMT) could not be obtained, we attempted to obtain an active
motor threshold (AMT). The presence of an AMT was confirmed
by elicitation of 30% of the maximum voluntary contraction of the
contralateral extensor digitorum musculature with a resultant
motor-evoked potential of 50mV peak to peak. If neither of these
were found, the subject was excluded from the study to promote
reasonable homogeneity across subjects and because the presence
of an elicitable motor-evoked potential is more favorable to higher
recovery of function.23,24 The study was approved by The Insti-
tutional Review Board of the University of Minnesota and Gillette
Children’s Specialty Healthcare. A parent/guardian of each child
gave informed consent, and each child gave assent.
Real rTMS plus mCIMT group
The rTMS and mCIMT interventions were therefore given in an
alternating daily design, allowing the children to tolerate the
intensive protocol. Long-lasting neuroplastic effects of rTMS have
been found in animal studies; however, such findings have not
been confirmed in humans.25,26 This group received 5 treatments
of real rTMS and 5 treatments of mCIMT on alternate weekdays
over 2 weeks. Each subject was seated in a reclining chair and
wore earplugs and a swim cap for marking stimulation points. A
70-mm figure-8 TMS coil connected to a Magstim 200 stimulatora
was handheld over the approximate hotspot area for the con-
tralesional M1 tangential to the scalp and was oriented with the
handle pointing posterolaterally at a 45 angle to the sagittal line.
To find the hotspot, the coil was moved systematically, and single-
pulse magnetic stimuli were delivered at approximately 0.1Hz,
starting at an intensity of 50% of the stimulator maximum. This
level was adjusted until the RMT or AMT was found, which was
defined as the minimum intensity required to elicit motor-evoked
potentials 50mV peak to peak in at least 3 of 5 trials with the
target muscle at rest. Responses from the unaffected extensor
digitorum muscle were monitored using electrodes connected to a
Cadwell Sierra Wedge electromyography amplifier.b
Once the hotspot and threshold were established, the child
received priming rTMS followed by 1-Hz rTMS to the contrale-
sional M1. Iyer et al6 found that in healthy individuals, 6-Hz
priming enhanced the suppressive effect of 1-Hz rTMS; howev-
er, similar effects in individuals with stroke have not yet been
confirmed. In theory, primed 1-Hz low-frequency rTMS to the
contralesional M1 inhibits the contralesional M1 while simulta-
neously boosting disinhibition of the ipsilesional M1. The key
methodologic action is the pairing of priming with low-frequency
rTMS. Delivery of 6-Hz priming alone to the contralesional M1 is
disadvantageous according to this theory.
Priming consisted of 10 minutes of 6-Hz rTMS at 90% of the
RMT delivered in 2 trains per minute with 5 seconds per train and
25-second intervals between trains (total of 600 priming pulses).
Priming was followed immediately by an additional 10 minutes of
1-Hz rTMS at 90% of the RMT without interruption (total of 600
low-frequency pulses). During rTMS, electromyographic activity
monitored the extensor digitorum, biceps brachii, first dorsal
interosseous, and gastrocnemius muscles of the unaffected side for
early signs of a possible seizure.On alternate days, children received individualized mCIMT for
the affected upper extremity. A univalve cast was fitted and
applied to the unaffected hand and arm. The cast remained on 24
hours per day, except for 1 hour during the rTMS intervention.
During that hour, the cast was temporarily removed to allow for
range of motion checks, skin integrity checks, neurologic exami-
nation, washing, and electrode attachment for that session.
mCIMT treatment was performed for 2 hours with a trained
therapist. The mCIMT treatments consisted of shaping and re-
petitive activities for function, range of motion, and strengthening
of the affected upper extremity.27 Children continued to use their
affected limb during home functional activities and a documented
caregiver-supervised home program.
Sham rTMS and mCIMT group
These children received the same intervention as the real rTMS
plus mCIMT group except that a sham rTMS coil was used to
mimic the sound and tactile sensation on the scalp (from the small
electrical stimulator component unique to the sham coil) of the
rTMS without stimulation.a This coil has been found to be valid
for application in unknowing subjects, and no subject in our study
reported prior exposure to TMS.28
Safety measures
Safety measures for this study were established by a multidisci-
plinary team and consisted of the monitoring of subject responses,
medical assessments, and behavioral assessments, including both
ipsilateral and contralateral hand function. Safety measures were
administered in the same order to all subjects within the study.
Assessments at pretest, posttest, and each rTMS
session
Physician assessment
Using a modified Pediatric Stroke Outcome Measure,29 the
physician assessed motor, cognitive, gait, spasticity, and visual
field status and assigned a Gross Motor Function Classification
System level.30 Specific areas evaluated included attention, ability
to follow commands, cranial nerves, muscle tone assessed with a
modified Ashworth Scale,31 deep tendon reflexes, presence or
absence of clonus, strength, ability to perform rapid alternating
movements, balance, and gait. Physician assessments occurred at
each TMS session.
Vital signs
Blood pressure and heart rate values were taken at all testing and
rTMS intervention sessions.
Subject report of symptoms assessment
Questions were asked about the occurrence or change of any of the
following items: seizure, headache, neck pain, dental pain, hear-
ing, nausea, abnormal muscle contractions, dizziness, abnormal
sleep, difficulty in concentration, anxiety, memory, mood, balance,
and use of the unaffected hand (appendix 2).18 These questions
were based on adverse events from rTMS that have been reported
in the literature. If a symptom occurred, the child and caregiver
were asked about the onset, duration, and severity of the symptom.
If medical care was deemed necessary, a medical team was onsite
to address further issues. A follow-up within 24 hours was
documented as well to assess status.www.archives-pmr.org
Pediatric brain stimulation safety S107Pretest and posttest: ipsilateral unaffected hand
function and assessments
Accuracy index
Functional MRI evaluated brain reorganization and will be re-
ported elsewhere. Relative to safety, subjects performed a finger
movement tracking task during the functional MRI. Wearing
potentiometersc on the index finger at the metacarpophalangeal
joint on both hands, subjects attempted to track a displayed target
waveform with finger extension/flexion movements of the desig-
nated hand. The unaffected hand performance was used to eval-
uate possible regression of function.
Finger strength
Subjects placed their unaffected index finger into a ring with a
load cell measuring finger extension force.32,d,e Maximum finger
extension force was determined as the greatest of 3 trials.
Stereognosis
Sensibility affects use of the involved upper extremity, including
hand function and acquisition of new motor tasks.33 Many chil-
dren with cerebral palsy and spastic hemiparesis have concurrent
deficits in sensibility, and using stereognostic assessment has been
beneficial in understanding of functional effects and subsequent
rehabilitation treatment design.34
The 12-object stereognosis test evaluated the subject’s ability,
with vision shielded, to identify 12 different common objects
individually placed in their unaffected hand and then affected
hand.34 Scoring was based on correct identification of the objects,
with fully intact functioning scoring a 12.
Cognitive function
To understand the capability to follow commands and the potential
effect of the intervention on neural networks other than the motor
system, cognitive testing was incorporated. These tests also
allowed informal assessment of the potential needs a child may
have had in the rigors of intervention participation. The Token
Test for Children assessed receptive language function, specif-
ically the child’s ability to move tokens of varied sizes and shapes
according to specific directions.35 Also, the Digit Span Test, a
component of the Wechsler Intelligence Scale for Children-
Revised, assessed the ability of the child to remember and recite
a list of increasing numbers read to the child aloud.36
Subject questionnaire
This survey is a component of a larger survey developed to
determine the child’s reaction to single-pulse TMS.37 Within this
self-report questionnaire, rating scales for subjective report of
satisfaction, willingness to repeat the study, and likelihood of
recommending the study to others were assessed.
Statistical analysis
This study was designed to evaluate safety and feasibility prior to
initiating larger trials. At the time of study construct there were no
preliminary data from our laboratory or from any other study
involving rTMS combined with constraint-induced movement
therapy in children with which to conduct a power analysis. The
literature showed a total number of participants between 10 and 20
in the studies using rTMS in adults with stroke.5,18,38 Kirton et al17
recruited 10 subjects in an rTMS pediatric hemiparesis study. The
initial sample size was 30 children. Because of recruitmentwww.archives-pmr.orgchallenges, the resultant sample size of 19 children with hemi-
paresis in this exploratory pilot study was defined based on
these studies.
All analyses were conducted using the as-treated study popu-
lation to evaluate safety. Because both the sham and real treat-
ments were correctly administered, this population is the same as
the intent-to-treat study population. Medians and ranges are
reported for continuous variables; counts and percentages are
reported for categorical variables. Continuous variables were
compared using a Wilcoxon rank-sum test between groups, and
categorical variables were compared using a Fisher exact test.
Changes from pretest to posttest were computed and compared
using a Wilcoxon signed-rank test. In addition, an analysis of
covariance was computed for the change from pretest to posttest to
compare groups while controlling for baseline scores. Safety
outcomes between groups were evaluated from a clinical
perspective to identify differences prior to achieving statistical
significance. In this manner, we evaluated the presence of poten-
tial observed trends toward significance as a manner of mini-
mizing any potential harmful effects for any group. Analyses were
conducted using R software version 2.15.0.f
Results
We screened 203 children; 184 of them were excluded. The
remaining 19 children were randomized into 2 intervention groups
(fig 2). All children who entered treatment completed the study.
Subjects were enrolled over a 24-month period from 2010 to
2012. Patient characteristics are listed in table 1, along with di-
agnoses of cortical ischemic lesions confirmed by MRI. All
children received mCIMT. Ten children received real rTMS and
had a median age of 10.5 years (mean, 10.82.7y; range, 8e15y).
Eight had right-sided hemiparesis, and 2 had left-sided hemi-
paresis. One of these participants had a Manual Ability Classifi-
cation System level score of I, and the remaining 9 children had a
level II score. In the sham rTMS group, the median age was 10
years (mean, 10.93.1; range, 8e15y). Four children had right
hemiparesis, and 5 had left hemiparesis. Three children had a
Manual Ability Classification System level I score, 5 had a level II
score, and 1 had a level III score. All children had a Gross Motor
Function Classification System level of 1. No statistically signif-
icant differences were found between groups at baseline for
any measure.
Safety measures
Seizures
No seizures were observed in the participants.
Physician assessment
The physician found no serious adverse events; therefore, no
treatment was withheld.
Vital signs
The blood pressure and heart rate measurements remained within
normative values for all subjects during each rTMS session.39
Subject report of symptoms
Out of 133 TMS and rTMS testing and intervention sessions and
90 mCIMT sessions, the most common rTMS-related complaint
was headache and the most common mCIMT-related complaint
was irritation because of the cast on the unaffected arm. Common
Potential 
Subjects who 
expressed 
interest 
(n=203)
Pursued Medical 
Records (n=82)
Appropriate by initial screen.
Invited for Onsite Screening 
(n=46)
Excluded by phone screen alone (n=121)
Incompatible Diagnosis (n=36)
Not compatible with MRI (n=2)
Seizure History (n=9)
Age of subject at infarct (n=12)
Age of subject (n=31)
Language and Cognition (n=2)
Distance (n=7)  
Lack of follow-up from family (n=17)
Safety Concerns (n=2)
Personal Reasons (n=3)
Excluded after MR Review (n=26) 
Incompatible Diagnosis (n=15)
Seizure History (n=3)
Age of subject at infarct (n=1)
Medication (n=1)
Lack of follow-up from family  (n=2)
Safety Concerns (n=1)
Personal Reasons (n=2)
Distance (n=1)
Excluded After Enrollment (n=17)
No MEP (n=11)
No Hand Impairment (n=2)
Incompatible MRI Diagnosis (n=4)
Approved: Lack of follow-up from family 
after notification (n=10)
Screened Onsite (n=36)
Excluded Prior to Enrollment (n=0)
Enrolled (n=36)
Randomized (n=19)
rTMS + mCIMT Group (n=10) rTMS + mCIMT Group (n=9)
Family did not return 
HIPAA (n=10)
Fig 2 Consolidated Standards of Reporting Trials diagram. Abbreviations: HIPAA, Health Insurance Portability and Accountability Act; MEP,
motor-evoked potential; MR, medical record; rTMSreal, real rTMS group; rTMSsham, sham rTMS group.
S108 B.T. Gillick et alterminology criteria for adverse event ratings for all events were 1,
indicating a mild event. All headaches subsided during the same
session by clipping the elastic band of the swim cap orTable 1 Subject demographics
Participant Group Sex Age (y) Stroke Location
1 Real F 15 Basal ganglia, lateral ventricle
2 Real M 8 Anterior limb internal capsule, post
capsule, thalamus, putamen
3 Real M 8 Anterior limb internal capsule, thal
centrum semiovale
4 Real M 8 Middle cerebral artery frontal pariet
5 Real F 12 Middle cerebral artery frontal pariet
6 Real M 9 Internal capsule, thalamus, putame
corona radiata, periventricular wh
7 Real M 11 Frontoparietal cortex, internal caps
putamen, centrum semiovale
8 Real F 15 Middle cerebral artery to frontal lob
9 Real F 11 Right post frontal lobe, centrum se
10 Real F 13 Centrum semiovale, thalamus, basal
11 Sham F 15 Periventricular white matter
12 Sham M 8 Middle cerebral artery, centrum sem
13 Sham M 8 Anterior limb internal capsule, thal
14 Sham M 12 Basal ganglia, thalamus, centrum se
15 Sham F 8 Posterior frontal lobe, corona radia
16 Sham F 8 Centrum semiovale, posterior limb i
caudate, putamen
17 Sham M 16 Corona radiata, thalamus, basal gan
18 Sham F 11 Middle cerebral artery frontal tempo
19 Sham F 15 Centrum semiovale, thalamus, basal
Abbreviations: F, female; GMFCS, Gross Motor Function Classification System s
right; Real, real rTMS plus mCIMT group; Sham, sham rTMS plus mCIMT groupadministering an age appropriate dose of acetaminophen or
ibuprofen. Complaints of cast irritation were resolved by adjusting
the cast contact position by providing additional padding orSide of
Hemiparesis
MACS
Score
GMFCS
Score
R II I
erior limb internal R II I
amus, putamen, R II I
al lobes R II I
al, basal ganglia, thalamus R II I
n, lentiform nucleus, globus pallidus,
ite matter
R II I
ule, thalamus, caudate, R II I
e L I I
miovale L II I
ganglia R II I
L I I
iovale R I I
amus, putamen, basal ganglia R II I
miovale L II I
ta, centrum semiovale L II I
nternal capsule, thalamus, R II I
glia R II I
ral parietal lobes R III I
ganglia L I I
core; L, left; M, male; MACS, Manual Ability Classification Scale score; R,
.
www.archives-pmr.org
Fig 3 Accuracy index of the unaffected hand. Means for the real
rTMS plus mCIMT group are represented by the bold orange line for the
pre- to posttest, and the sham rTMS plus mCIMT group are shown in
purple. Individuals in either group are noted by thin lines of corre-
sponding colors.
Pediatric brain stimulation safety S109replacing the cast. All symptoms subsided within 24 hours,
assessed either by phone or by next-day treatment, depending on
the day of the week. No other complaints were reported (table 2).
Finger tracking
The median change in the unaffected hand performance in the
accuracy index was 1.93 (mean, 6.9335.36; range, 68.6 to
47.5) in the real rTMS group and 7.42 (mean, 12.0314.42;
range, 1.2 to 39.3) in the sham group (PZ.15). Because of the
decline in performance in the real rTMS group compared with the
sham group, we examined individual trajectories. We found that
the performance of 2 children in the rTMS group decreased sub-
stantially in the posttest. These children experienced fatigue dur-
ing the MRI procedures but performed well on other posttest
measures. One participant in each group was missing finger
tracking data (fig 3).Table 2 Reported side effects
Side Effect
Real rTMS Plus mCIMT Group (NZ10)
No. of Children
With Complaints
Total Overall No.
of Complaints
Headache 5 10
Cast irritation 3 3
Anxiety 3 4
Dizziness 2 2
Tingling 2 2
Mood changes 1 1
Concentration 2 2
Abnormal muscle contractions 1 1
Nausea 0 0
Stomachache 1 1
Fatigue 1 1
www.archives-pmr.orgFinger strength
The median change in the unaffected index finger extension force
was 1.65N (mean, 0.944.19N; range, 6.5 to 5.6N) in the
real rTMS group and 0.63N (mean, 1.334.92; range, 11.8
to 5.7N) in the sham group (PZ.75).
Stereognosis
All children achieved the maximum score of 12 using the unaf-
fected hand in the pre- and posttest sessions.
Token Test for Children
The median change in the Token Test for Children scores was 0.5
(mean, 1.33.4; range, 4.5 to 1.0) in the real rTMS group and
0.0 (mean, 0.53.7; range, 2.2 to 1.2) in the sham group
(PZ.70). One participant in the sham group was missing data.
Digit Span Test
The median change in the Digit Span Test was 0.00 (mean,
0.01.20; range, .250 to 0.25) in the real rTMS group and 0.5
(mean, 0.381.41; range, 1.0 to 1.0) in the sham
group (PZ.68).
Subject questionnaire
The subject questionnaire rating satisfaction (0e10 scale, where
10 is the most satisfied) yielded a median score of 7 for the
children in the real rTMS group (interquartile range, 5.5e9.75)
and 9 (interquartile range, 7e10) in the sham group (PZ.35).
When asked about repeating the study, 90% of the children in the
real rTMS group and 100% of the children in the sham group
stated they would do the study again (PZ1.0). All children stated
they would recommend enrollment in the study to others. TMS
was most frequently described as a tapping sensation (nZ11/19,
58%). The most enjoyable aspect of the TMS study was relaxing
during intervention (nZ8/19, 42%), and the least enjoyable was
the tapping sensation (nZ4/19, 21%) and the casting (nZ2/
19, 11%).
Importantly, an unbiased evaluative source, the Data Safety
Monitoring Board, found that the observed adverse events were
minor and did not warrant altering the protocol or discontinuation
of the study. As an added measure, 1 week after the posttest, the
investigators discussed, by phone, the cognitive and behavioralSham rTMS Plus mCIMT Group (NZ9) Comparing the No. of
Children With Complaints
Between Groups (P)
No. of Children
With Complaints
Total Overall No.
of Complaints
8 8 .141
4 4 .650
1 1 .582
1 2 .999
1 1 .999
1 2 .999
0 0 .477
1 1 .999
2 2 .744
1 1 .999
1 1 .999
S110 B.T. Gillick et alstatus with the caregivers and school teachers for all children. No
statements of concern in performance were raised. Also, all
families and subjects were queried regarding blindedness to the
study, and no breech of blinding was found.
Discussion
This study evaluated the safety of 6-Hz primed low-frequency
rTMS combined with mCIMT in 19 children with stroke.
Comprehensive safety evaluation tools were used in the domains
of behavior, cognition, physician clinical assessment, subject
symptom report, satisfaction questionnaire, and Data Safety
Monitoring Board assessment. Attempts to establish homoge-
neity across subjects was established by inclusion of children
who had both ipsilesional and contralesional motor-evoked
potentials through TMS assessment. The results of this
comprehensive assessment suggest that 5 treatments of 600
pulses of intermittent 6-Hz rTMS followed by 600 pulses of
continuous 1-Hz rTMS given at 90% of the RMT to the con-
tralesional M1 and combined with mCIMT was safe for the
children in this study.
Numerous studies have shown low-frequency rTMS to the
contralesional M1 to be safe (ie, no serious adverse events) in
stroke; this was most recently reported by Kakuda et al.19
Several studies have demonstrated safety with high-frequency
priming of low-frequency rTMS to the contralesional M1 in
adults with stroke.18,40 Because of the potential risk for seizure
with high-frequency rTMS intervention, the current study is the
first, to our knowledge, to show that high-frequency priming
before low-frequency rTMS can be applied without serious
adverse events in children with stroke. Applying 6-Hz priming of
low-frequency rTMS to the contralesional hemisphere in chil-
dren with hemiparesis was used to theoretically may prove to
achieve greater disruption of interhemispheric inhibition than
low-frequency settings alone. With safety verified in this study,
further studies comparable with the work in healthy subjects by
Iyer et al6 are now needed in stroke research comparing the
efficacy of priming while continuing to monitor safety along
with efficacy.
Rarely, serious adverse events have occurred in children with
stroke during low-frequency rTMS to the contralesional M1. Kir-
ton et al41 reported that 2 children experienced neurocardiogenic
syncope. Further investigation disclosed that both subjects had
positive histories of presyncope and fainting. We integrated this
information in our study by screening for a history of fainting to
minimize this potential adverse event. In addition, onsite vital signs
were assessed at each rTMS visit, and subjects were positioned
semirecumbent. We requested that all children have a regular meal
and maintain adequate hydration during all sessions.
Minor adverse events did occur in this study in both the real
rTMS and sham groups. However small, all symptoms were
noted as recommended by Machii et al.42 Headache was the most
common complaint, followed by nausea. This is consistent with
other reports in which 113 healthy adult participants in 1270
experimental sessions were monitored for minor adverse
events.43 Minor adverse events were found to be higher in initial
TMS sessions compared with continuing sessions. Other rTMS
studies have reported minor adverse events (eg, headache,43
nausea44). Many of the same symptoms were shared by both
the real rTMS and sham groups in our study, suggesting that the
source of the symptoms was similar. Anxiety was found to be
present during 6 interventions, 5 of which were in the real rTMSgroup. Further analysis showed that 3 anxiety reports were from
1 individual in the real rTMS group, who also reported headache,
cast irritation, difficulty concentrating, and transient unaffected
arm tingling. During this subject’s participation in the study, the
Data Safety Monitoring Board and consultants assessed the
subject’s continuation in the study. Because the reports were
assigned a Common Terminology Criteria for Adverse Events
rating of 1 (mild), the decision was made to continue. As indi-
cated on the posttest questionnaire, this subject would repeat the
study, recommend it to family and friends, and rated the expe-
rience a 7 out of 10 overall. The subject’s main complaints were
related to becoming comfortable and familiar with wearing
the cast.
The most prevalent casting minor adverse events were skin
irritation, redness, and impaired performance of activities of daily
living, education, play, leisure, and social participation. However,
no child resisted application of the cast, and all children
completed the study without untimely cast removal. Similar re-
ports have also been noted regarding adjustment to casting during
mCIMT, with similar modifications to enable continued
participation.45
Although safety is of paramount importance when creating a
study design that addresses the complex needs of children with
congenital hemiparesis, the feasibility of running such a study is
also central to determine the value of future clinical in-
terventions. We contend that our study has demonstrated feasi-
bility of combining rTMS plus mCIMT in children with stroke
by the observation that all children who entered the study and
received treatment completed the study. Also, when queried, all
19 children stated that they would recommend enrollment to a
friend or family member. Detailed understanding of the in-
tricacies of working with the pediatric population and under-
standing the perception of the child’s experience are central to
the success of such a study.46
Study limitations
The small sample size is a limitation in this study. Generalizing
results to a larger population, especially outside of the 8- to 17-
year age range, should be made with caution. To promote safety
and avoid fatigue, rTMS and mCIMT interventions were given on
alternating days. With this alternate day paradigm, it is possible
that the optimal time period for synergizing rTMS effects with
mCIMT effects was missed.
With safety now demonstrated, it would seem reasonable in
future work to apply the behavioral training the same day as the
rTMS, with an appropriate intervening break to avoid fatigue.
Only with continued studies and diligent reporting of all adverse
events will the full impact of rTMS alone and in combination with
behavioral interventions in children with hemiparesis be known.
Future investigation of not only the dosing parameters but also
interindividual variability in physiological response to interven-
tion and hormonal, genetic, developmental, and other influences
may play key roles in the determination of the safety and optimal
response to use of rTMS.
Conclusions
This study demonstrated that 6-Hz primed low-frequency rTMS
can be applied safely in the understudied population with pediatric
hemiparesis. Key components to assess safety include the
following: thorough screening prior to inclusion for history of
conditions (eg, syncope, seizures); review of medical records andwww.archives-pmr.org
Pediatric brain stimulation safety S111imaging results; and behavioral, cognitive, and subject tolerance
reports. In future studies, considerations for safety remain para-
mount but at the same time allow for pursuit of optimal rTMS
intensity, frequency, duration, and behavioral intervention
parameters.
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Date
Symptom (y or n) 
Seizure
Headache
Neck pain 
Dental pain 
Hearing
Nausea
Abnormal 
muscle contractions 
Dizziness
Abnormal sleep 
Difficult 
concentration 
Anxiety
Memory 
Mood
Balance
Use of strong hand 
Onset of 
menstruation 
Changes in 
menstruation 
Other (describe 
below)
Comments: 
Appendix 2 Subject report of symptoms
www.archives-pmr.orgAppendix 1 Study Inclusion and Exclusion
Criteria
Inclusion criteria are as follows:
 Congenital hemiparesis caused by arterial ischemic stroke that
occurred before, during, or within 1 year of birth or periven-
tricular leukomalacia confirmed by MRI
 Current age between 8 and 17 years
 Presence of 10 of active metacarpophalangeal joint flexion and
extension on the affected hand
 Presence of a resting or active ipsilesional motor-evoked po-
tential as assessed using TMS
Exclusion criteria are as follow:
 Multiple strokes
 Metabolic disorders
 Neoplasm
 Seizure within the previous 2 years
 Disorders of cellular migration and proliferation
 Hemorrhage
 Receptive aphasia
 Pregnancy
 Indwelling metal or medical devices incompatible with MRI or
TMS
 Claustrophobia
 Gross visual field cuts that would interfere with tasks performed
during MRI
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